參考文獻(xiàn)/References:
[1] Lagmay J P,Krailo M D,Dang H,et al.Outcome of patients with recurrent osteosarcoma enrolled in seven phase ii trials through children's cancer group,pediatric oncology group,and children's oncology group: learning from the past to move forward [J].J Clin Oncol,2015,34(25):3031-3038.[2] Sayles L C,Breese M R,Koehne A L,et al.Genome-Informed targeted therapy for osteosarcoma[J].Cancer Discov,2019,9(1):46-63.[3] Brown H K,Tellez-Gabriel M,Heymann D.Cancer stem cells in osteosarcoma [J].Cancer Lett,2017,386:189-195.[4] Zhong Z H,Mao S F,Lin H F,et al.Comparative proteomics of cancer stem cells in osteosarcoma using ultra-high-performance liquid chromatography and Orbitrap Fusion mass spectrometer [J].Talanta,2018,178:362-368.[5] Robin P,Singh K,Suntharalingam K.Gallium(iii)-polypyridyl complexes as anti-osteosarcoma stem cell agents[J].Chem Commun(Camb),2020,56(10):1509-1512.[6] Honda K,Yamada T,Hayashida Y,et al.Actinin4 increases cell motility and promotes lymph node metastasis of colorectal cancer [J].Gastroenterology,2005,128(1):5162.[7] Liu X,Chu K M.α-Actinin-4 promotes metastasis in gastric cancer [J].Lab Invest,2017,97(9):1084-1094.[8] Jung J, Kim S, An H T, et al.α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer[J].Carcinogenesis,2020,41(7):940-949.[9] Fukushima S,Yoshida A,Honda K,et al.Immunohistochemical actinin4 expression in infiltrating gliomas: Association with who grade and differentiation [J].Brain tumor pathology,2014,31(1):1116.[10] Wang N,Wang Q,Tang H,et al.Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells [J].J Exp Clin Cancer Res,2017,36(1):172.[11] Huang Q, Li X, Huang Z, et al.ACTN4 promotes the proliferation, migration, metastasis of osteosarcoma and enhances its invasive ability through the NF-κB pathway [J].Pathol Oncol Res,2020,26(2):893-904.[12] Tirino V,Desiderio V,Paino F,et al.Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo[J].FASEB J,2011,25(6):2022-2030.[13] 洪峰,袁高樂,張輝潔,等.微管不穩(wěn)定蛋白和CD133在骨肉瘤組織的表達(dá)及其臨床意義[J].中華實(shí)驗(yàn)外科雜志,2017,34(3):516-518.[14] Xu N,Kang Y,Wang W,et al.The prognostic role of CD133 expression in patients with osteosarcoma[J].Clin Exp Med,2020,20(2):261-267.[15] Zhang Y Y,Tabataba H, Liu X Y, et al.ACTN4 regulates the stability of RIPK1 in melanoma [J].Oncogene,2018,37(29):4033-4045.
相似文獻(xiàn)/References:
[1]林文韜 王武煉 肖莉莉 張怡元.基于GEO數(shù)據(jù)庫發(fā)現(xiàn)骨肉瘤關(guān)鍵基因GMFG及其生物學(xué)功能[J].福建醫(yī)藥雜志,2020,42(02):112.
LIN Wentao,WANG Wulian,XIAO Lili,et al.Identification of the key gene GMFG and its biological function in osteosarcoma based on GEO database[J].FUJIAN MEDICAL JOURNAL,2020,42(05):112.
[2]肖莉莉 劉 暉 賈春鋒.基于核酸適配體的微流控芯片的構(gòu)建及對(duì)循環(huán)腫瘤細(xì)胞篩選性能的測(cè)定[J].福建醫(yī)藥雜志,2020,42(02):119.
[3]陳康堯,顧恩毅,蔡碰德,等.H1受體拮抗劑異丙嗪對(duì)順鉑治療骨肉瘤的影響及機(jī)制[J].福建醫(yī)藥雜志,2021,43(04):132.
CHEN Kangyao,GU Enyi,CAI Pengde,et al.Efficacy and mechanism of H1 receptor antagonist promethazine on osteosarcoma treated with cisplatin[J].FUJIAN MEDICAL JOURNAL,2021,43(05):132.
[4]林東澤.shRNA沉默c-myc基因?qū)G-63骨肉瘤細(xì)胞c-myc/PD-L1軸的影響[J].福建醫(yī)藥雜志,2022,44(05):133.
[5]周子杰,張家豪,姜吉霖,等.miR-586通過SFRP1調(diào)控骨肉瘤細(xì)胞增殖、遷移、侵襲的機(jī)制研究[J].福建醫(yī)藥雜志,2024,46(01):115.[doi:10.20148/j.fmj.2024.01.032]